Bausch Health Companies (TSE:BHC) has released an update.
Bausch Health Companies, along with Salix Pharmaceuticals, has initiated a patent lawsuit against Amneal Pharmaceuticals, seeking to protect its gastrointestinal drug, XIFAXAN®. The lawsuit was filed in response to Amneal’s attempt to market a generic version of the drug, challenging the enforceability and validity of Bausch Health’s patents. Bausch Health has successfully defended its XIFAXAN® intellectual property in the past, settling previous challenges with several other pharmaceutical companies.
For further insights into TSE:BHC stock, check out TipRanks’ Stock Analysis page.
